Success Story: EB1A Approved Despite RFE! We Helped a Translational Medicine Expert Secure Success with Premium Processing Service
Client’s Testimonial:
"I am very pleased to have my application approved. I feel your firm has some expert attorneys who made a very strong application both at the initial and RFE stages.”
On August 26th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Physician in the Field of Translational Medicine (Approval Notice).
General Field: Translational Medicine
Position at the Time of Case Filing: Physician
Country of Origin: Pakistan
Country of Residence at the Time of Filing: Qatar
Approval Notice Date: August 26th, 2026
Processing Time: 10 months, 25 days (Premium Processing Upgrade Requested)
Case Summary:
Translational medicine connects scientific findings with practical approaches to diagnosis and patient care. The client built his career in this field by studying complex medical conditions, including adverse drug reactions, genetic factors associated with disease, and unusual complications of infectious diseases. One particularly influential contribution identified an uncommon clinical presentation associated with COVID-19, helping broaden understanding of how the disease could initially manifest.
For the client’s EB-1A (Alien of Extraordinary Ability) petition, we presented evidence under the judging, original contributions, and scholarly authorship criteria. His relevant credentials included:
- 16 peer-reviewed journal articles and 11 abstracts, including 5 first-authored abstracts
- At least 18 completed peer reviews
- A body of research that had accumulated hundreds of citations
- 2 papers ranked among the top 10% most-cited Clinical Medicine articles from their year of publication
Rather than presenting these numbers as sufficient on their own, the petition demonstrated what they revealed about the client’s standing in translational medicine. Independent researchers across numerous countries had cited his findings when investigating drug-related health risks, genetic influences on disease, and complications associated with COVID-19. We highlighted specific examples showing how researchers relied on his work to inform subsequent investigations. His repeated invitations to review scholarly work, together with his editorial responsibilities, provided additional evidence that the scientific community trusted his expertise to evaluate the work of other professionals.
The petition was also supported by two recommendation letters, including one from an independent expert familiar with the client through his published research. These letters contextualized the objective record and explained the broader significance of his contributions.
“There is thus no doubt that [Client] shall continue to produce additional valuable analysis, both driving progress in the field and bringing immense benefits to national and international concerns.”
Taken together, the evidence supported not only the individual EB-1A criteria but also the final merits argument that the client had achieved sustained recognition and significant influence in his field. After USCIS issued an RFE and reviewed the additional evidence, the client’s I-140 EB-1A petition was ultimately approved, allowing him to continue pursuing his work in translational medicine in the United States.